WHO Drug Information Vol. 20, No. 4, 2006 - World Health ...

WHO Drug Information, Vol. 20, No. 4, 2006 Proposed INN: List 96
alvespimycinum
alvespimycin (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-{[2-(dimethylamino)=
ethyl]amino}-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-
3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-
9-yl carbamate
antineoplastic
alvespimycine carbamate de (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-{[2-
(diméthylamino)éthyl]amino}-13-hydroxy-8,14-diméthoxy-
4,10,12,16-tetraméthyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-
1(21),4,6,10,18-pentaén-9-yle
antinéoplasique
alvespimicina carbamato de (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-[[2-
(dimetilamino)etil]amino]-13-hidroxi-4,10,12,16-tetrametil-
8,14-dimetoxi-3,20,22-trioxo-2-azabiciclo[16.3.1]docosa-
1(21),4,6,10,18-pentaen-9-ilo
antineoplásico
C32H48N4O8
amifampridinum
amifampridine pyridine-3,4-diamine
potassium channel blocker
N
O
N
H
CH 3
O
H
NH
H3CO H3C O HO H
H H H
CH3 OCH3 CH3 amifampridine pyridine-3,4-diamine
bloqueur des canaux potassiques
amifampridina piridina-3,4-diamina
bloqueador de los canales de potasio
H 3C
C5H7N3
N
CH 3
NH 2
NH 2
467214-20-6
O NH 2
H
O
54-96-6
283